REPL
Replimune Group, Inc.
REPL
Replimune Group, Inc.
New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed a
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) violations of §§10(
SAN DIEGO, Aug. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acqui
If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc
WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou
SAN DIEGO, July 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Replimune Group, Inc. (NASDAQ: REPL) or certain of its executive officers violated state or federal securitie